General Information

Actonel has been approved as a new therapy for treating Paget's disease of the bone.

Clinical Results

Approval is based on an 18-month, double-blind, active-controlled pivotal trial of 123 patients with moderate-to-severe Paget's disease, which showed disease remission in the majority of patients who received Actonel.